<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02212782</url>
  </required_header>
  <id_info>
    <org_study_id>DW1029M-I-6</org_study_id>
    <nct_id>NCT02212782</nct_id>
  </id_info>
  <brief_title>the Pharmacokinetic Profiles of Linagliptin With DW1029M</brief_title>
  <acronym>PLID</acronym>
  <official_title>A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Study to Evaluate DW1029M Influence the Pharmacokinetic Profiles of Linagliptin After Oral Administration in Healthy Male Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong Wha Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong Wha Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of
      Linagliptin after oral administration in healthy male volunteer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, open-label, multiple-dose, crossover phase I clinical study to evaluate DW1029M
      influence the pharmacokinetic profiles of Linagliptin after oral administration in healthy
      male volunteer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax and AUC</measure>
    <time_frame>1st day and 43rd day, 5th day and 47th day, 6th day and 48th day : Predose(0, morning), 7th day and 49th day : Predose(0), 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour</time_frame>
    <description>Maximum of Concentration(Cmax), Area Under Plasma Concentration-Time Curve(AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of Plasma</measure>
    <time_frame>1st day and 43rd day, 5th day and 47th day, 6th day and 48th day : Predose(0, morning), 7th day and 49th day : Predose(0), 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour</time_frame>
    <description>Maximum drug concentration time(Tmax), Half-time(t1/2), Apparent renal clearance(CL/F), Apparent volume of distribution(Vd/F), Fluctuation[(Css,max-Css,min)/Css,av], Swing[(Css,max-Css,min)/Css,min]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st oral administration of Linagliptin 5mg and 2nd oral administration of DW1029M 1200mg and Linagliptin 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st oral administration of DW1029M 1200mg and Linagliptin 5mg and 2nd oral administration of Linagliptin 5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin 5mg</intervention_name>
    <description>Linagliptin 5mg once daily for 7 days</description>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_label>B Group</arm_group_label>
    <other_name>Trajenta Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW1029M 1200mg and Linagliptin 5mg</intervention_name>
    <description>Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days</description>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_label>B Group</arm_group_label>
    <other_name>Concomitant of DW1029M 1200mg and Linagliptin 5mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy adult within the range of 19 to 55 years old at the time of screening

          -  Body Mass Index(BMI)=17.5~30.5kg/m2, one with weight of more than 55kg (BMI= kg/(m)2)

          -  Congenital or chronic diseases within the last three years, there is no medical
             examination results of popular characters with no psychotic symptoms or findings

          -  Doctor checks conducted hematology, blood chemistry, urinalysis and laboratory tests,
             including an electrocardiogram(EKG) performed during screening tests such as a
             suitable test subjects who judged

          -  The purpose of the test participants prior to testing, information, and to hear about
             the free will fully explain to participate in this study, according to the
             Institutional Review Board(IRB)-approved consent form signed by the parties in writing

        Exclusion Criteria:

          -  one with clinically significant blood, kidneys, endocrine, respiratory,
             gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or
             allergic disease (but ,except for untreated seasonal allergies of asymptomatic at the
             time of administration) with medical history or evidence

          -  one with gastrointestinal disease(Such as esophageal stricture or achalasia of the
             esophagus disease, Crohn disease) to affect drug absorption or surgery(but, excluding
             simple appendectomy or hernia surgery) with medical history

          -  Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) &gt; 2 times the upper
             limit of the normal range

          -  Within 6 months, 210 g / week of alcohol in excess of a history of regular characters
             (beer (5%) 1 cup (250 mL) = 10 g, soju(20%) 1 cup (50 mL) = 8 g, Wine (12%) 1 cup (125
             mL) = 12 g)

          -  Take part in other clinical trials within two months

          -  Systolic Blood Pressure(SBP) ≥ 140 mmHg or Diastolic Blood Pressure (DBP) ≥ 90 mmHg

          -  The great history of alcohol or drug abuse within 1 year

          -  Taking medication of drug-metabolizing enzymes that are known to significantly induce
             or inhibit within 30 days

          -  More than 20 cigarettes a day smoker

          -  Taking medication of a prescription drug or nonprescription within 10 days,

          -  Within two months the whole blood donation have, within one month of the apheresis
             donation have

          -  Participate in clinical trials to test drug administration and may be at increased
             risk due to interpretation of test results, or may interfere with severe supply /
             chronic medical or mental condition or abnormal laboratory test values in character

          -  Patient with hypersensitivity to investigational products or ingredients

          -  Patient with Type 1 Diabetes or Diabetic ketoacidosis

          -  Described lifestyle in this protocol can comply with or can not

          -  One with other investigator judge to unsuitable
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingul Kim, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabukdo</state>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

